PatientsVille.com Logo


Galantamine Medical Research Studies

Up-to-date List of Galantamine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Galantamine Medical Research Studies

Rank Status Study
1 Recruiting Effects of Galantamine on Cognition
Condition: Schizophrenia
Interventions: Drug: Galantamine;   Drug: Galantamine or Placebo
Outcome Measures: Determine effect of drug on cognition;   Determine the effect of the drug on ability to express or experience emotions
2 Recruiting Effect of Galantamine on Short-term Abstinence
Condition: Tobacco Use Disorder
Interventions: Drug: Galantamine;   Drug: Placebo
Outcome Measures: Total number of smoke-free days (biochemically verified) during a 7-day quit attempt.;   Cognitive performance;   Subjective symptoms;   Side effects of Galantamine
3 Recruiting Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Oxytocin;   Drug: Galantamine or placebo Galantamine;   Drug: Placebo
Outcome Measures: Scale for the Assessment of Negative Symptoms (SANS) total score;   Neurocognitive assessment battery composite score;   P-50 Testing;   Eye Tracking measures;   Brief Psychiatric Rating Scale (BPRS);   Calgary Depression Scale (CDS);   Clinical Global Impressions (CGI);   Arizona Sexual Experience Questionnaire ASEX;   Likert-type Scale for Social Engagement;   Simpson-Angus Scale (SAS);   MPRC-TD scale;   Barnes Akathisia Scale (BAS);   Fagerstrom Test of Nicotine Dependence (FTND);   Side Effect Checklist (SEC);   Vital Signs;   EKG;   Laboratory measures
4 Recruiting Galantamine Smoking Study
Condition: Nicotine Dependence
Interventions: Drug: placebo;   Drug: Galantamine 8mg;   Drug: Galantamine 16mg
Outcome Measures: Smoking Self Administration;   Smoking Abstinence
5 Unknown  Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)
Condition: Alzheimer's Disease
Interventions: Drug: Galantamine (Reminyl®);   Drug: Placebo/Galantamine (Reminyl®)
Outcome Measure:
6 Recruiting Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
Conditions: Stroke;   Cognitive Impairment
Interventions: Drug: Galantamine;   Drug: placebo
Outcome Measure: fMRI
7 Recruiting Alzheimer and Sleep
Condition: Alzheimer's Disease
Intervention: Drug: Galantamine and Donepezil
Outcome Measures: Comparison of the percentage of paradoxical sleep recorded with polysomonography in 65 years old patients with administration of Galantamine or Donépézil;   Describe the iatrogenic modifications of rhythm and architecture of sleep. describe the iatrogenic modifications of rythm and architecture of sleep
8 Recruiting Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
Condition: Addiction
Interventions: Drug: Galantamine;   Drug: Placebo
Outcome Measures: Urine Toxicology;   Heart Rate;   Blood Pressure;   CANTAB RVIP measure;   CANTAB SST;   Stroop;   Digit Span
9 Unknown  Galantamine in the Treatment of Post-Traumatic Headache
Conditions: Post-Traumatic Headache;   Head Trauma,Closed;   Retention Disorders,Cognitive
Intervention: Drug: Galantamine
Outcome Measures: Primary Headache Efficacy Measure; number of pain free days after 3 months;   Consumption of rescue medication;   Number of days with moderate or severe headache after 3 months.
10 Recruiting Symptomatic Treatment of Vascular Cognitive Impairment
Conditions: Mild Cognitive Impairment (Vascular);   Mild Cognitive Disorder (Vascular);   Vascular Dementia
Interventions: Drug: Galantamine;   Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: Change on performance on executive function and on memory after active challenge;   Change on performance on other Neurocart tests after active challenge
11 Recruiting Effect of Galantamine on Short-term Abstinence
Conditions: Treatment-seeking Smokers, Reporting Consumption of at Least 10 Cigarettes;   Per Day for at Least the Past 6 Months
Intervention: Drug: Galantamine Hydrobromide-ER
Outcome Measure: Number of Adverse Events
12 Recruiting Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Cholinesterase Inhibitor;   Drug: Placebo
Outcome Measures: Clinician's Global Impression of Change (CGIC);   Number of total adverse events
13 Recruiting Comparative Research of Alzheimer's Disease Drugs
Conditions: Dementia;   Alzheimer's Disease
Interventions: Drug: Donepezil;   Drug: Galantamine;   Drug: Rivastigmine
Outcome Measures: Discontinuation and Adherence Rates;   Neuropsychiatric Inventory (NPI);   HABC Monitor
14 Recruiting A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Condition: Lewy Body Disease
Intervention: Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Outcome Measures: Change from baseline in perfusion brain SPECT at 6 months;   Change from baseline in neuropsychological assessment scores at 6 months;   Volumetric Brain MRI
15 Recruiting Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction
Conditions: Dementia;   Cognitive Impairment
Outcome Measures: Number of patients taking alternative medicines;   Numbers of potential and clinical relevant interactions;   The patient's subjective experiences with alternative medicines
16 Recruiting Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Conditions: Alzheimer Disease;   Mild Cognitive Impairment;   Delirium, Dementia, Amnestic, Cognitive Disorders
Intervention: Drug: Donepezil
Outcome Measures: Change over time in Selective Reminding Test (SRT) Scores;   Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog);   Clinician's Interview Based Impression (CIBIC-plus);   Pfeffer Functional Activities Questionnaire (FAQ);   Measurement of Everyday Cognition (Ecog)
17 Unknown  Clinical Trial of Donepezil Between the Naive Group and the Switching Group
Conditions: Alzheimer's Disease;   Dementia
Intervention: Drug: donepezil
Outcome Measures: Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K);   Seoul Activities of Daily Living (S-ADL);   Seoul-Instrumental Activities of Daily Living (S-IADL);   Korean Neuropsychiatric Inventory (K-NPI)
18 Recruiting The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
Conditions: Alzheimer Disease;   Dementia;   Brain Diseases;   Central Nervous System Diseases;   Nervous System Diseases;   Tauopathies;   Neurodegenerative Diseases;   Delirium, Dementia, Amnestic, Cognitive Disorders;   Mental Disorders
Intervention: Biological: NEUROSTEM®-AD
Outcome Measures: Safety;   Efficacy

These studies may lead to new treatments and are adding insight into Galantamine etiology and treatment.

A major focus of Galantamine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Galantamine